Stacy Moulder

8.8k total citations · 2 hit papers
70 papers, 4.7k citations indexed

About

Stacy Moulder is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Stacy Moulder has authored 70 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 28 papers in Molecular Biology. Recurrent topics in Stacy Moulder's work include Advanced Breast Cancer Therapies (23 papers), Cancer-related Molecular Pathways (15 papers) and PI3K/AKT/mTOR signaling in cancer (14 papers). Stacy Moulder is often cited by papers focused on Advanced Breast Cancer Therapies (23 papers), Cancer-related Molecular Pathways (15 papers) and PI3K/AKT/mTOR signaling in cancer (14 papers). Stacy Moulder collaborates with scholars based in United States, United Kingdom and Germany. Stacy Moulder's co-authors include Hope S. Rugo, Karen A. Gelmon, Véronique Dièras, Richard S. Finn, Dongrui R. Lu, Seock‐Ah Im, Miguel Martín, Oleg Lipatov, Nadia Harbeck and Janice M. Walshe and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Nature Biotechnology.

In The Last Decade

Stacy Moulder

68 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Palbociclib and Letrozole in Advanced Breast Cancer

2016 1.9k citations Richard S. Finn, Miguel Martín et al. profile →
Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes

2021 413 citations Ruli Gao, Shanshan Bai et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stacy Moulder United States	29	2.7k	2.6k	1.7k	1.6k	705	70	4.7k
Vandana G. Abramson United States	34	2.7k 1.0×	1.3k 0.5×	1.4k 0.8×	1.2k 0.8×	360 0.5×	119	4.9k
Eva Ciruelos Spain	32	5.3k 2.0×	2.3k 0.9×	1.5k 0.9×	2.4k 1.5×	523 0.7×	208	7.1k
María Koehler United States	26	5.0k 1.9×	3.4k 1.3×	1.5k 0.9×	1.9k 1.2×	1000 1.4×	112	7.0k
Sophia Randolph United States	21	4.7k 1.8×	4.6k 1.8×	1.6k 0.9×	1.6k 1.0×	1.2k 1.7×	69	6.8k
Otto Metzger United States	30	3.2k 1.2×	1.4k 0.5×	1.4k 0.8×	1.7k 1.1×	278 0.4×	117	4.8k
Zsuzsanna Pápai Hungary	20	1.7k 0.6×	1.6k 0.6×	1.2k 0.7×	951 0.6×	343 0.5×	94	3.2k
Emma Clark United Kingdom	20	5.1k 1.9×	1.7k 0.7×	1.2k 0.7×	1.6k 1.0×	406 0.6×	50	6.2k
Gaia Schiavon United Kingdom	28	2.5k 1.0×	1.7k 0.7×	1.5k 0.9×	1.9k 1.2×	222 0.3×	105	4.6k
Judy Dering United States	23	2.2k 0.8×	1.3k 0.5×	1.5k 0.9×	902 0.6×	324 0.5×	41	3.6k
Shin‐ichiro Fujiwara Japan	14	2.5k 0.9×	3.0k 1.2×	1.9k 1.1×	1.2k 0.7×	169 0.2×	91	4.6k

Countries citing papers authored by Stacy Moulder

Since Specialization

Citations

This map shows the geographic impact of Stacy Moulder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stacy Moulder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stacy Moulder more than expected).

Fields of papers citing papers by Stacy Moulder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stacy Moulder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stacy Moulder. The network helps show where Stacy Moulder may publish in the future.

Co-authorship network of co-authors of Stacy Moulder

This figure shows the co-authorship network connecting the top 25 collaborators of Stacy Moulder. A scholar is included among the top collaborators of Stacy Moulder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stacy Moulder. Stacy Moulder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Powell, Reid T., Amanda L. Rinkenbaugh, Lei Guo, et al.. (2024). Targeting neddylation and sumoylation in chemoresistant triple negative breast cancer. npj Breast Cancer. 10(1). 37–37. 2 indexed citations

Gao, Ruli, Shanshan Bai, Ying C. Henderson, et al.. (2021). Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nature Biotechnology. 39(5). 599–608. 413 indexed citations breakdown →

Reddy, T. P., Roberto R. Rosato, Xiaoxian Li, et al.. (2020). A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Research. 22(1). 121–121. 99 indexed citations

Powell, Emily, Jiansu Shao, Christopher A. Bristow, et al.. (2018). A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. npj Breast Cancer. 4(1). 9–9. 39 indexed citations

Turner, Nicholas C., Richard S. Finn, Miguel Martín, et al.. (2018). Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Annals of Oncology. 29(3). 669–680. 69 indexed citations

Doostan, Iman, Cansu Karakaş, Matthew J. Ellis, et al.. (2017). Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clinical Cancer Research. 23(23). 7288–7300. 35 indexed citations

Vijayaraghavan, Smruthi, Stacy Moulder, Khandan Keyomarsi, & Rachel M. Layman. (2017). Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Targeted Oncology. 13(1). 21–38. 67 indexed citations

Hatzis, Christos, W. Fraser Symmans, Ya Zhang, et al.. (2015). Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. Clinical Cancer Research. 22(1). 26–33. 44 indexed citations

Wheler, Jennifer J., Johnique T. Atkins, Filip Jankú, et al.. (2015). Multiple gene aberrations and breast cancer: lessons from super-responders. BMC Cancer. 15(1). 442–442. 13 indexed citations

10.

Mitri, Zahi, Cansu Karakaş, Caimiao Wei, et al.. (2015). A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Investigational New Drugs. 33(4). 890–894. 56 indexed citations

11.

Silva, Grace O., Xiaping He, Joel S. Parker, et al.. (2015). Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. Breast Cancer Research and Treatment. 152(2). 347–356. 36 indexed citations

12.

Wheler, Jennifer J., Filip Jankú, Gerald S. Falchook, et al.. (2014). Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemotherapy and Pharmacology. 73(3). 495–501. 47 indexed citations

13.

Gagliato, Débora De Melo, Denis L. Jardim, Gerald S. Falchook, et al.. (2014). Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit. Clinical Breast Cancer. 14(6). 468–474. 37 indexed citations

14.

González-Angulo, Ana M., Funda Meric‐Bernstam, Sant P. Chawla, et al.. (2013). Weekly nab -Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial. Clinical Cancer Research. 19(19). 5474–5484. 63 indexed citations

15.

Wheler, Jennifer J., Apostolia M. Tsimberidou, David S. Hong, et al.. (2012). Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Annals of Oncology. 23(8). 1963–1967. 14 indexed citations

16.

Jankú, Filip, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, et al.. (2011). PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. Molecular Cancer Therapeutics. 10(3). 558–565. 289 indexed citations

17.

Akli, Saïd, Tuyen Bui, Hannah F. Wingate, et al.. (2010). Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors. Clinical Cancer Research. 16(4). 1179–1190. 41 indexed citations

18.

Moulder, Stacy, Kai Yan, Fei Huang, et al.. (2010). Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy. Molecular Cancer Therapeutics. 9(5). 1120–1127. 27 indexed citations

19.

André, Fabrice, Christos Hatzis, Ludovic Lacroix, et al.. (2007). Vav3, a Rho GTPase guanine nucleotide exchange factor, represents a potential novel therapeutic target for breast cancer. Cancer Research. 67. 4422–4422. 1 indexed citations

20.

Moulder, Stacy, Nikola Valkov, Jana Gump, et al.. (2006). Is cytoplasmic localization of topoisomerase I (topo I) a mechanism of resistance for topo I inhibitors? Results from an NCCN sponsored phase II trial of gemcitabine and irinotecan in metastatic breast cancer.. Cancer Research. 66. 1270–1271. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact